-
公开(公告)号：US20200237748A1
公开(公告)日：2020-07-30
申请号：US16844767
申请日：2020-04-09
IPC分类号： A61K31/4748 , A61K47/32 , A61K47/12 , A61K9/70 , A61K9/00 , A61F13/02 , A61K31/485
摘要： A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance. This mixture forms dispersed deposits in the pressure-sensitive adhesive. The buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.
-
公开(公告)号：US11583505B2
公开(公告)日：2023-02-21
申请号：US16406254
申请日：2019-05-08
摘要： The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment (3) and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer (1) and an adhesive polymer layer (2) that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layers 1 and 2.
-
公开(公告)号：US11529345B2
公开(公告)日：2022-12-20
申请号：US16844767
申请日：2020-04-09
IPC分类号： A61K31/4748 , A61K31/485 , A61K9/70 , A61F13/02 , A61K9/00 , A61K47/12 , A61K47/32
摘要： A transdermal therapeutic system for the transdermal administration of buprenorphine comprising a buprenorphine-containing self-adhesive layer structure having (A) a buprenorphine-impermeable backing layer, and (B) a buprenorphine-containing pressure-sensitive adhesive layer on the backing layer. The buprenorphine-containing adhesive layer comprises (a) at least one polymer-based pressure-sensitive adhesive, (b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, (c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of the buprenorphine-containing pressure-sensitive adhesive layer, and (d) a carboxylic acid selected from oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof. The amount of the carboxylic acid is sufficient so that the analgesically effective amount of buprenorphine is solubilized in the carboxylic acid to form a mixture including the viscosity-increasing substance. This mixture forms dispersed deposits in the pressure-sensitive adhesive. The buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.
-
公开(公告)号：US20200253957A1
公开(公告)日：2020-08-13
申请号：US16863584
申请日：2020-04-30
发明人： Gabriel Wauer , Thomas Hille , Kevin John Smith , Gillian Elizabeth Mundin , Helen Elizabeth Johnson
IPC分类号： A61K31/485 , A61K9/70 , A61K47/12 , A61K47/32
摘要： The invention relates to a method of treating pain in a patient by applying a transdermal therapeutic system for the transdermal administration of buprenorphine for 7 days on the skin of a patient, said transdermal therapeutic system comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing matrix layer on said buprenorphine-impermeable backing layer, the matrix layer comprising a) a polymer base, b) buprenorphine, and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the polymer base, and C) a skin contact layer on said buprenorphine-containing matrix layer comprising a polymer-based pressure-sensitive adhesive, and optionally wherein the buprenorphine-containing self-adhesive layer structure contains said buprenorphine in an amount of less than 0.8 mg/cm2 buprenorphine base or an equimolar amount of a pharmaceutically acceptable salt thereof.
-
公开(公告)号：US10335377B2
公开(公告)日：2019-07-02
申请号：US15126701
申请日：2015-03-16
摘要： The invention relates to a medical product for a fastening duration of at least 7 days having good skin compatibility. The medical product includes a central adhesive compartment (3) and an over-patch. The over-patch is free of active ingredients and is formed from a water-vapor-permeable back layer (1) and an adhesive polymer layer (2) that is free of active ingredients. The invention further relates to a method for the production of the foregoing medical product, and to kits of parts containing laminates of layers 1 and 2.
-
公开(公告)号：US12121616B2
公开(公告)日：2024-10-22
申请号：US17048036
申请日：2019-04-11
发明人： Gabriel Wauer , Frank Seibertz
CPC分类号： A61K9/7061 , A61F13/0276 , A61K9/7053 , A61K9/7069 , A61K9/7084 , A61K31/27 , A61K31/4748 , A61K47/14 , A61K47/32 , A61F2013/0296
摘要： The present invention relates to transdermal therapeutic systems (TTS) for the transdermal administration of solifenacin.
-
公开(公告)号：US11964060B2
公开(公告)日：2024-04-23
申请号：US16488506
申请日：2018-02-26
发明人： Thomas Hille , Gabriel Wauer , Petra Botzem , Frank Seibertz
CPC分类号： A61K9/7084 , A61K31/465 , A61K47/32 , A61K47/34 , A61P25/34 , C09J7/385
摘要： The invention relates to transparent therapeutic systems (TTS) which contain the active substance nicotine and which further contain at least one acid amide group as a lateral functional group. The TTS can be transparent and for discreet use. The invention also relates to methods for producing these TTS, said TTS being produced by methods using said polymers and being charged with active substance by way of a printing method.
-
公开(公告)号：US20200316055A1
公开(公告)日：2020-10-08
申请号：US16905476
申请日：2020-06-18
IPC分类号： A61K31/4748 , A61K31/485 , A61K9/70 , A61F13/02 , A61K9/00 , A61K47/12 , A61K47/32
摘要： The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof, c) a viscosity-increasing substance in an amount of about 0.1% to about 8% of said buprenorphine-containing pressure-sensitive adhesive layer, and d) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid, linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture including said viscosity-increasing substance, and wherein the carboxylic acid-, buprenorphine- and viscosity-increasing substance-containing mixture forms dispersed deposits in the said pressure-sensitive adhesive, and wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.
-
公开(公告)号：US20200306204A1
公开(公告)日：2020-10-01
申请号：US16778920
申请日：2020-01-31
发明人： Thomas Hille , Gabriel Wauer , Kevin John Smith , Helen Elizabeth Johnson , Gillian Elizabeth Mundin
IPC分类号： A61K9/70 , A61K31/485 , A61K47/12 , A61K31/4748
摘要： The invention relates to transdermal therapeutic system for the transdermal administration of buprenorphine, comprising a buprenorphine-containing self-adhesive layer structure comprising A) a buprenorphine-impermeable backing layer, and B) e a buprenorphine-containing pressure-sensitive adhesive layer on said buprenorphine-impermeable backing layer, the adhesive layer comprising a) at least one polymer-based pressure-sensitive adhesive, b) an analgesically effective amount of buprenorphine base or a pharmaceutically acceptable salt thereof and c) a carboxylic acid selected from the group consisting of oleic acid, linoleic acid and linolenic acid, levulinic acid and mixtures thereof, in an amount sufficient so that said analgesically effective amount of buprenorphine is solubilized therein to form a mixture, and the carboxylic acid buprenorphine mixture forms dispersed deposits in the said pressure-sensitive adhesive, wherein said buprenorphine-containing pressure-sensitive adhesive layer is the skin contact layer.
-
-
-
-
-
-
-
-
搜索结果
9 条记录 (耗时 0.014 秒)
